Search and analyse G-BA early benefit assessments
/
- Decisions
- 1,064
- Patient groups
- 1,748
- Patient groups with added benefit
- 35%
- Decisions in 2026
- 92
Latest decisions
Browse all decisions A to Z →- 2026-10-01ExdensurDepemokimabNot proven
- 2026-10-01ExdensurDepemokimabNot proven: 2 of 2 patient groups
- 2026-10-01LynkuetElinzanetantNot proven
- 2026-10-01LynkuetElinzanetantNot proven: 2 of 2 patient groups
- 2026-10-01BlenrepBelantamab-MafodotinNot proven: 2 of 2 patient groups
- 2026-10-01BlenrepBelantamab-MafodotinNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2026-10-01ZynyzRetifanlimabMinor
- 2026-10-01ZynyzRetifanlimabNon-quantifiable
- 2026-09-03UpliznaInebilizumabNot proven: 2 of 2 patient groups
- 2026-09-03UpliznaInebilizumabNon-quantifiable
- 2026-09-03AkeegaNiraparib/AbirateronacetatNot proven: 2 of 2 patient groups
- 2026-09-03InluriyoImlunestrantNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2026-09-03NucalaMepolizumabNot proven
- 2026-08-20ColxiColchicinMinor
- 2026-08-20MounjaroTirzepatidNot proven
- 2026-08-20TepezzaTeprotumumabNot proven: 3 of 3 patient groups
- 2026-08-20DawnzeraDonidalorsenMinor
- 2026-08-20EluciremGadopiclenolNot proven
- 2026-08-20TibsovoIvosidenibNot proven
- 2026-08-20TibsovoIvosidenibNot proven
The interface is translated. The G-BA decision texts are only available in German.